

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.**

**百奥赛图(北京)医药科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2315)**

### **VOLUNTARY ANNOUNCEMENT**

#### **ENTERING INTO RENLITE LICENSING AGREEMENT WITH JANSSEN**

The board (the “**Board**”) of directors (the “**Directors**”) of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the “**Company**” or “**Biocytogen**”, together with its subsidiaries, the “**Group**”) is pleased to announce the entering into a non-exclusive license agreement (the “**License Agreement**”) with Janssen Biotech, Inc. (“**Janssen**”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the License Agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was led by Johnson & Johnson Innovation LLC.

RenLite is a member of Biocytogen’s fully human antibody RenMice® family. RenLite mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream chemistry, manufacturing, and controls processes (CMC) development.

As of June 30, 2022, Biocytogen has licensed its proprietary fully human antibody RenMice® platforms to 16 biopharmaceutical companies around the world, including Merck Healthcare KGaA, Xencor, BeiGene and Innovent. Using the fully human antibody RenMice platforms, the antibody discovery platform of Biocytogen develops fully human antibodies molecular for more than 1,000 potentially druggable targets. As of June 30, 2022, Biocytogen has reached 28 antibody drug licensing/co-development agreements with partners including Merck Healthcare KGaA, China Resources Biopharm, Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) and RemeGen Co., Ltd.. 11 new agreements have been reached in the first half of 2022 alone. In the second half of 2022, Biocytogen further reached antibody/sequences licensing agreements with partners including Hansoh Pharma, ADC Therapeutics, FineImmune, etc, and also entered into licensing agreements of clinical/preclinical antibody molecules with partners such as Chipscreen NewWay Biosciences and Syncromune. The antibody discovery platform of Biocytogen has been continuously producing antibody molecules with great potential and has been reaching co-development/licensing agreements with biotech and biopharmaceutical companies around the world at different stages.

With the development of our collaborators' research and development projects based on RenMice license and the progress of the research and development of the licensed/transferred antibody molecules, Biocytogen is expected to receive considerable long-term benefits including development milestones in revenue and royalties. With the increasing recognitions of Biocytogen's antibody technology platforms and antibody development capabilities from the biotech industry, we expect that there will be more and more RenMice platform licensing and antibody molecules co-development/licensing agreements reached. Antibody development business will become a solid source of continuous growth of the Company's revenue.

To the best knowledge and belief of the Directors, as of the date of this announcement, Janssen and its ultimate beneficial owner are independent of, and not connected with, the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")). The transactions contemplated under the License Agreement do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

**This is a voluntary announcement made by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Biocytogen Pharmaceuticals (Beijing) Co., Ltd.**  
**Shen Yuelei**

*Chairman of the Board, Chief Executive Officer and Executive Director*

Hong Kong, 8 March, 2023

*As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.*

## **Biocytogen Announces RenLite® Licensing Agreement with Janssen**

BEIJING, March 8, 2023 — Biocytogen today announced the entering into the License Agreement with Janssen, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the License Agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was led by Johnson & Johnson Innovation LLC.

RenLite is a member of Biocytogen’s fully human antibody RenMice® family. RenLite mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream chemistry, manufacturing, and controls processes (CMC) development.

“We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients,” said Dr. Yuelei Shen, Founder, Chairman and Chief Executive Officer of Biocytogen.

### **About RenMice®**

RenMice® are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab®, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for *in situ* replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus *in situ* to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).

RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.

As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent, etc.

## **About Biocytogen**

Biocytogen (Stock Code: 02315.HK) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab<sup>®</sup>/RenLite<sup>®</sup>/RenNano<sup>®</sup> mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its *in vivo* drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1,000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice<sup>®</sup> licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany.

For more information, please visit <http://en.biocytogen.com.cn>.

## **Forward-Looking Statements**

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.